https://m2.mtmt.hu/ hun 2026-10-24 13:55 JournalArticle 31997570 VALIDATED true Cited By :1 Export Date: 17 November 2021 Correspondence Address: Valerieva, A.; Department of Allergology, Bulgaria; email: anna.valerieva@gmail.com 0 false 2026-10-21T07:40:13.641+0000 2021-06-02T08:51:17.129+0000 2021-05-04T07:49:24.329+0000 true 10062250 Molnár-Taga Márta /api/admin/10062250 Admin Molnár-Taga Márta (SE 4-es admin) true 10062250 2026-07-09T11:00:25.985+0000 2026-07-09T11:00:25.985+0000 2021-05-04T08:22:01.639+0000 true 10062250 Molnár-Taga Márta /api/admin/10062250 Admin Molnár-Taga Márta (SE 4-es admin) true 10062250 true false true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle true 10000059 Article true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle /api/subtype/10000059 Szakcikk SubType Szakcikk (Folyóiratcikk) 101 true 10000059 true 1 /api/category/1 Category Tudományos true 1 Valerieva, A. true true /api/journal/10022315 REVIEWED WORLD ALLERGY ORGANIZATION JOURNAL (WAO) 1939-4551 1939-4551 true false 10022315 false 10022315 true 1939-4551 1939-4551 Journal FOREIGN 14 4 100535 100535 8 2021 Background: Hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency (C1-INH-HAE) is characterized by recurrent swelling attacks. A European treatment registry was established to review the adverse event profile and efficacy of recombinant human C1 esterase inhibitor (rhC1-INH) for HAE attacks. Methods: Individuals with C1-INH-HAE were enrolled following a decision to treat with rhC1-INH and provision of written informed consent. Medical history and baseline HAE information were collected at screening. Healthcare providers entered data on HAE attacks, response to treatment, and adverse events using a web-based questionnaire. Results: From July 1, 2011, through December 1, 2019, 71 patients with C1-INH-HAE (30 male/41 female; mean age, 47.3 years; age range, 19–78 years) in 9 countries reported 2356 attacks and were treated with rhC1-INH. Before registry entry, patients, including 20 (28.2%) who were on maintenance therapy/prophylaxis at registry enrollment, experienced a mean of 25 HAE attacks per year (median, 16 [range, 0–185]). Most treated HAE attacks were abdominal (46.1%), followed by peripheral (38.3%), oro-facial-pharyngeal (14.8%), urogenital (3.2%), and laryngeal (2.6%). The mean rhC1-INH dose was 3307 U (43.3 U/kg). Patients reported symptom improvement within 4 h for 97.8% of attacks (2305/2356) with rhC1-INH; most attacks (99.8%; 2351/2356) required only 1 dose. Five attacks were treated with a second dose (total rhC1-INH dose administered for attack, 4200 U). No hypersensitivity, thrombotic/thromboembolic events, or drug-related serious adverse events were reported. Conclusion: The rhC1-INH treatment registry provided real-world data on the treatment of 2356 HAE attacks that were consistent with clinical trial data of rhC1-INH in patients with C1-INH-HAE. © 2021 The Authors true 2021 true true true false true false GOLD 2026-10-21 true https://doi.org/10.1016/j.waojou.2021.100535 8 0 8 7 0 8 8 7 8 8 8 7 7 7 1 0 8 7 8 7 0 6 6 Folyóiratcikk Journal Article 24 8 Könyvrészlet Chapter in Book 25 0 Könyv Book 23 0 Egyéb konferenciaközlemény Conference paper 31 0 Egyéb konferenciakötet Conference proceedings 32 0 Oltalmi formák Protection forms 26 0 Disszertáció Thesis 28 0 Egyéb Miscellaneous 29 0 Alkotás Achievement 22 0 Kutatási adat Research data 33 0 Folyóiratcikk Journal Article 24 0 0 0 Könyvrészlet Chapter in Book 25 0 0 0 Könyv Book 23 0 0 0 Egyéb konferenciaközlemény Conference paper 31 0 0 0 Egyéb konferenciakötet Conference proceedings 32 0 0 0 Oltalmi formák Protection forms 26 0 0 0 Disszertáció Thesis 28 0 0 0 Egyéb Miscellaneous 29 0 0 0 Alkotás Achievement 22 0 0 0 Kutatási adat Research data 33 0 0 0 2021 0 1 1 1 1 2022 0 0 0 0 0 2023 0 1 0 1 0 2024 0 5 5 5 5 2025 0 1 1 1 1 Q1 false false false false 2021-05-03T08:22:01.475+0000 Belgyógyászati és Hematológiai Klinika (SE / AOK / K) 2 10 1 11 0 true Language 10002 /api/language/10002 Angol Angol English true 2 true PersonAuthorship 96179602 /api/authorship/96179602 Valerieva, A. ✉ 1 0.09090909 true false true Valerieva A. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96179603 /api/authorship/96179603 Staevska, M.T. 2 0.09090909 false false false Staevska M.T. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96179604 /api/authorship/96179604 Grivcheva-Panovska, V. 3 0.09090909 false false false Grivcheva-Panovska V. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96179605 /api/authorship/96179605 Jesenak, M. 4 0.09090909 false false false Jesenak M. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96179606 /api/authorship/96179606 Kőhalmi, K.V. [Kőhalmi, Kinga Viktória (immunológia), szerző] Belgyógyászati és Hematológiai Klinika (SE / AOK / K) 5 0.091 false false false Author 10048193 /api/author/10048193 Kőhalmi Kinga Viktória (immunológia) Kőhalmi Kinga Viktória true 10048193 true Kőhalmi K.V. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96179607 /api/authorship/96179607 Hrubiskova, K. 6 0.09090909 false false false Hrubiskova K. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96179608 /api/authorship/96179608 Zanichelli, A. 7 0.09090909 false false false Zanichelli A. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96179609 /api/authorship/96179609 Bellizzi, L. 8 0.09090909 false false false Bellizzi L. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96179610 /api/authorship/96179610 Relan, A. 9 0.09090909 false false false Relan A. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96179611 /api/authorship/96179611 Hakl, R. 10 0.09090909 false false false Hakl R. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96179612 /api/authorship/96179612 Farkas, H. [Farkas, Henriette (klinikai immunoló...), szerző] Belgyógyászati és Hematológiai Klinika (SE / AOK / K) 11 0.091 false true false Author 10009711 /api/author/10009711 Farkas Henriette (klinikai immunológus, allergológus) Farkas Henriette true 10009711 true Farkas H. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PublicationIdentifier 18739161 /api/publicationidentifier/18739161 DOI: 10.1016/j.waojou.2021.100535 PlainSource 6 /api/publicationsource/6 DOI PublicationSourceType 10001 /api/publicationsourcetype/10001 DOI true true true DOI DOI https://doi.org/@@@ true true 6 true GOLD true IDENTICAL 10.1016/j.waojou.2021.100535 https://doi.org/10.1016/j.waojou.2021.100535 false true PublicationIdentifier 18877498 /api/publicationidentifier/18877498 WoS: 000647796400004 PlainSource 1 /api/publicationsource/1 WoS PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true WoS WoS https://www.webofscience.com/wos/woscc/full-record/@@@ true true 1 true IDENTICAL 000647796400004 https://www.webofscience.com/wos/woscc/full-record/000647796400004 false true PublicationIdentifier 18739160 /api/publicationidentifier/18739160 Scopus: 85104577151 PlainSource 3 /api/publicationsource/3 Scopus PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true Scopus Scopus http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@ true true 3 true IDENTICAL 85104577151 http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85104577151 false true PublicationIdentifier 18877499 /api/publicationidentifier/18877499 PubMed: 33995818 PlainSource 17 /api/publicationsource/17 PubMed PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true PubMed PubMed http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=@@@&dopt=Abstract true true 17 true IDENTICAL 33995818 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=33995818&dopt=Abstract false true Classification 12324 /api/classification/12324 Általános- és belgyógyászat true true Classification 12309 /api/classification/12309 Hematológia true true Keyword 11247 /api/keyword/11247 Complement C1 Inhibitor Protein true 11247 true Keyword 17606 /api/keyword/17606 REGISTRY true 17606 true Keyword 1020094 /api/keyword/1020094 Angioedema true 1020094 true Keyword 1153078 /api/keyword/1153078 HEREDITARY true 1153078 true Keyword 2304268 /api/keyword/2304268 Recombinant human C1 esterase inhibitor true true Keyword 2304269 /api/keyword/2304269 Ruconest true true SjrRating 11234580 /api/sjrrating/11234580 sjr:Q1 (2021) Scopus - Pulmonary and Respiratory Medicine WORLD ALLERGY ORGANIZATION JOURNAL (WAO) 1939-4551 24 0.24 journal RatingType 10002 /api/ratingtype/10002 sjr sjr true true ClassificationExternal 2740 /api/classificationexternal/2740 Scopus - Pulmonary and Respiratory Medicine true 2740 true Q1 DIRECT true true Reference 20224416 /api/reference/20224416 1. Magerl, M., Frank, M., Lumry, W., Short-term prophylactic use of C1-inhibitor concentrate in hereditary angioedema: findings from an international patient registry (2017) Ann Allergy Asthma Immunol, 118 (1), pp. 110-112 1 false true Reference 20224415 /api/reference/20224415 2. Riedl, M.A., Bygum, A., Lumry, W., Safety and usage of C1-inhibitor in hereditary angioedema: Berinert registry data (2016) J Allergy Clin Immunol Pract, 4 (5), pp. 963-971 2 false true Reference 20224414 /api/reference/20224414 3. Zanichelli, A., Maurer, M., Aberer, W., Long-term safety of icatibant treatment of patients with angioedema in real-world clinical practice (2017) Allergy, 72 (6), pp. 994-998 3 false true Reference 20224413 /api/reference/20224413 4. Zanichelli, A., Longhurst, H.J., Maurer, M., Misdiagnosis trends in patients with hereditary angioedema from the real-world clinical setting (2016) Ann Allergy Asthma Immunol, 117 (4), pp. 394-398 4 false true Reference 20224412 /api/reference/20224412 5. Hernández Fernandez de Rojas, D., Ibañez, E., Longhurst, H., Treatment of HAE attacks in the Icatibant Outcome Survey: an analysis of icatibant self-administration versus administration by health care professionals (2015) Int Arch Allergy Immunol, 167 (1), pp. 21-28 5 false true Reference 20224411 /api/reference/20224411 6. Caballero, T., Maurer, M., Longhurst, H.J., Triggers and prodromal symptoms of angioedema attacks in patients with hereditary angioedema (2016) J Investig Allergol Clin Immunol, 26 (6), pp. 383-386 6 false true Reference 20224410 /api/reference/20224410 7. Aberer, W., Maurer, M., Bouillet, L., Breakthrough attacks in patients with hereditary angioedema receiving long-term prophylaxis are responsive to icatibant: findings from the Icatibant Outcome Survey (2017) Allergy Asthma Clin Immunol, 13, p. 31 7 false true Reference 20224409 /api/reference/20224409 8. Bygum, A., Caballero, T., Grumach, A.S., Elderly versus younger patients with hereditary angioedema type I/II: patient characteristics and safety analysis from the Icatibant Outcome Survey (2019) Clin Transl Allergy, 9, p. 37 8 false true Reference 20224408 /api/reference/20224408 9. Caballero, T., Aberer, W., Longhurst, H.J., The Icatibant Outcome Survey: experience of hereditary angioedema management from six European countries (2017) J Eur Acad Dermatol Venereol, 31 (7), pp. 1214-1222 9 false true Reference 20224407 /api/reference/20224407 10. Longhurst, H.J., Dempster, J., Lorenzo, L., Real-world outcomes in hereditary angioedema: first experience from the Icatibant Outcome Survey in the United Kingdom (2018) Allergy Asthma Clin Immunol, 14, p. 28 10 false true Reference 20224406 /api/reference/20224406 11. Maurer, M., Bork, K., Martinez-Saguer, I., Management of patients with hereditary angioedema in Germany: comparison with other countries in the Icatibant Outcome Survey (2019) J Eur Acad Dermatol Venereol, 33 (1), pp. 163-169 11 false true Reference 20224405 /api/reference/20224405 12. Zuraw, B.L., Busse, P.J., White, M., Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema (2010) N Engl J Med, 363 (6), pp. 513-522 12 false true Reference 20224404 /api/reference/20224404 13. Cicardi, M., Levy, R.J., McNeil, D.L., Ecallantide for the treatment of acute attacks in hereditary angioedema (2010) N Engl J Med, 363 (6), pp. 523-531 13 false true Reference 20224403 /api/reference/20224403 14. Cicardi, M., Banerji, A., Bracho, F., Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema (2010) N Engl J Med, 363 (6), pp. 532-541 14 false true Reference 20224402 /api/reference/20224402 15. Forrest, C.B., Bartek, R.J., Rubinstein, Y., Groft, S.C., The case for a global rare-diseases registry (2011) Lancet, 377 (9771), pp. 1057-1059 15 false true Reference 20224401 /api/reference/20224401 16. Boulanger, V., Schlemmer, M., Rossov, S., Seebald, A., Gavin, P., Establishing patient registries for rare diseases: rationale and challenges (2020) Pharmaceut Med, 34 (3), pp. 185-190 16 false true Reference 20224400 /api/reference/20224400 17. Andrási, N., Veszeli, N., Holdonner, A., Evaluation of the efficacy and safety of home treatment with the recombinant human C1-inhibitor in hereditary angioedema resulting from C1-inhibitor deficiency (2020) Int Immunopharm, 80, p. 106216 17 false true Reference 20224399 /api/reference/20224399 18. Valerieva, A., Staevska, M., Jesenak, M., Recombinant human C1 esterase inhibitor as short-term prophylaxis in patients with hereditary angioedema (2020) J Allergy Clin Immunol Pract, 8 (2), pp. 799-802 18 false true Reference 20224398 /api/reference/20224398 19. Riedl, M.A., Grivcheva-Panovska, V., Moldovan, D., Recombinant human C1 esterase inhibitor for prophylaxis of hereditary angio-oedema: a phase 2, multicentre, randomised, double-blind, placebo-controlled crossover trial (2017) Lancet, 390 (10102), pp. 1595-1602 19 false true Reference 20224397 /api/reference/20224397 20. Farkas, H., Csuka, D., Veszeli, N., Zotter, Z., Szabó, E., Varga, L., Home treatment of attacks with conestat alfa in hereditary angioedema due to C1-inhibitor deficiency (2014) Allergy Asthma Proc, (3), pp. 255-259 20 false true Reference 20224396 /api/reference/20224396 21. Andrasi, N., Veszeli, N., Holdonner, A., Evaluation of the efficacy and safety of home treatment with the recombinant human C1-inhibitor in hereditary angioedema resulting from C1-inhibitor deficiency (2020) Int Immunopharm, 80, pp. 1-5 21 false true Reference 20224395 /api/reference/20224395 22. Zuraw, B., Cicardi, M., Levy, R.J., Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema (2010) J Allergy Clin Immunol, 126 (4), pp. 821-827. , e814 22 false true Reference 20224394 /api/reference/20224394 23. Riedl, M.A., Bernstein, J.A., Li, H., Recombinant human C1-esterase inhibitor relieves symptoms of hereditary angioedema attacks: phase 3, randomized, placebo-controlled trial (2014) Ann Allergy Asthma Immunol, 112 (2), pp. 163-169. , e161 23 false true Reference 20224393 /api/reference/20224393 24. Riedl, M.A., Levy, R.J., Suez, D., Efficacy and safety of recombinant C1 inhibitor for the treatment of hereditary angioedema attacks: a North American open-label study (2013) Ann Allergy Asthma Immunol, 110 (4), pp. 295-299 24 false true Reference 20224392 /api/reference/20224392 25. Moldovan, D., Reshef, A., Fabiani, J., Efficacy and safety of recombinant human C1-inhibitor for the treatment of attacks of hereditary angioedema: European open-label extension study (2012) Clin Exp Allergy, 42 (6), pp. 929-935 25 false true Reference 20224391 /api/reference/20224391 26. Li, H.H., Moldovan, D., Bernstein, J.A., Recombinant human-C1 inhibitor is effective and safe for repeat hereditary angioedema attacks (2015) J Allergy Clin Immunol Pract, 3 (3), pp. 417-423 26 false true Reference 20224390 /api/reference/20224390 27. Reshef, A., Grivcheva-Panovska, V., Kessel, A., Recombinant human C1 esterase inhibitor treatment for hereditary angioedema attacks in children (2019) Pediatr Allergy Immunol, 30 (5), pp. 562-568 27 false true Reference 20224389 /api/reference/20224389 28. Ruconest Summary of Product Characteristics (2020), https://www.ema.europa.eu/en/documents/product-information/ruconest-epar-product-information_en.pdf, (Accessed 1 September 2020) 28 false true Reference 20224388 /api/reference/20224388 29. (2020) Ruconest® (C1 esterase inhibitor [recombinant]) for intravenous use, lyophilized powder for reconstitution [package insert], , Pharming Americas B.V. Leiden, The Netherlands 29 false true Reference 20224387 /api/reference/20224387 30. Maurer, M., Magerl, M., Ansotegui, I., The international WAO/EAACI guideline for the management of hereditary angioedema — the 2017 revision and update (2018) Allergy, 73 (8), pp. 1575-1596 30 false true Reference 20224386 /api/reference/20224386 31. Zuraw, B.L., Clinical practice. Hereditary angioedema (2008) N Engl J Med, 359 (10), pp. 1027-1036 31 false true Reference 20224385 /api/reference/20224385 32. Aygören-Pürsün, E., Magerl, M., Maetzel, A., Maurer, M., Epidemiology of bradykinin-mediated angioedema: a systematic investigation of epidemiological studies (2018) Orphanet J Rare Dis, 13 (1), p. 73 32 false true /api/publication/31997570 Valerieva A. et al. Recombinant human C1 esterase inhibitor for hereditary angioedema attacks: A European registry. (2021) WORLD ALLERGY ORGANIZATION JOURNAL (WAO) 1939-4551 1939-4551 14 4<div class="JournalArticle Publication long-list"> <div class="authors"> <img title="Forrásközlemény" style="float: left" src="/frontend/resources/grid/publication-core-icon.png"> <img title="Idézőközlemény" style="float: left" src="/frontend/resources/grid/publication-citation-icon.png"> <div class="autype autype0"> <span class="author-name" >Valerieva A. ✉ </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Staevska M.T. </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Grivcheva-Panovska V. </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Jesenak M. </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10048193"><a href="/gui2/?type=authors&mode=browse&sel=10048193" target="_blank">Kőhalmi K.V. (<span class="authorship-author-name">Kőhalmi Kinga Viktória</span> <span class="authorAux-mtmt"> immunológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Klinikum">K</span>/Belgyógyászati és Hematológiai Klinika</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Hrubiskova K. </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Zanichelli A. </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Bellizzi L. </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Relan A. </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Hakl R. </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10009711"><a href="/gui2/?type=authors&mode=browse&sel=10009711" target="_blank">Farkas H. (<span class="authorship-author-name">Farkas Henriette</span> <span class="authorAux-mtmt"> klinikai immunológus, allergológus</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Klinikum">K</span>/Belgyógyászati és Hematológiai Klinika</span> </div> </div> <div class="title"><a href="/gui2/?mode=browse&params=publication;31997570" target="_blank">Recombinant human C1 esterase inhibitor for hereditary angioedema attacks: A European registry</a></div> <div> <span class="journal-title">WORLD ALLERGY ORGANIZATION JOURNAL (WAO)</span> <span class="journal-issn">(<a target="_blank" href="https://portal.issn.org/resource/ISSN/1939-4551">1939-4551</a> <a target="_blank" href="https://portal.issn.org/resource/ISSN/1939-4551">1939-4551</a>)</span>: <span class="journal-volume">14</span> <span class="journal-issue">4</span> <span class="page"> Paper 100535. 8 p. </span> <span class="year">(2021)</span> </div> <div class="pub-footer"> <span class="language" xmlns="http://www.w3.org/1999/html">Nyelv: Angol | </span> <span class="identifiers"> <span class="id identifier oa_GOLD" title=" Gold "> <a style="color:blue" title="10.1016/j.waojou.2021.100535" target="_blank" href="https://doi.org/10.1016/j.waojou.2021.100535"> DOI </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="000647796400004" target="_blank" href="https://www.webofscience.com/wos/woscc/full-record/000647796400004"> WoS </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="85104577151" target="_blank" href="http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85104577151"> Scopus </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="33995818" target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=33995818&dopt=Abstract"> PubMed </a> </span> </span> <OnlyViewableByAuthor><div class="ratings"> <div class="journal-subject">Folyóirat szakterülete: Scopus - Pulmonary and Respiratory Medicine&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Immunology&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q2</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Immunology and Allergy&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q2</div> </div></OnlyViewableByAuthor> <div class="publication-citation" style="margin-left: 0.5cm;"> <span title="Nyilvános idézőközlemények összesen, említések nélkül" class="citingPub-count">Nyilvános idéző összesen: 8</span> | Független: 7 | Függő: 1 | Nem jelölt: 0 | WoS jelölt: 7 | Scopus jelölt:&nbsp;8 | WoS/Scopus jelölt:&nbsp;8 | DOI jelölt:&nbsp;8 </div> <div class="publication-citation"> <a target="_blank" href="/api/publication?cond=citations.related;eq;31997570&sort=publishedYear,desc&sort=title"> Idézett közlemények száma: 6 </a> </div> <div class="mtid"><span class="long-pub-mtid">Közlemény: 31997570</span> | <span class="status-data status-VALIDATED"> Egyeztetett </span> Forrás Idéző | <span class="type-subtype">Folyóiratcikk ( Szakcikk ) </span> | <span class="pub-category">Tudományos</span> | <span class="publication-sourceOfData">Scopus</span> </div> <div class="lastModified">Utolsó módosítás: 2021.06.02. 10:51 Sághi-Keszthelyi Anna (SE_KK_Admin5_SKA, admin) </div> <pre class="comment" style="margin-top: 0; margin-bottom: 0;"><u>Megjegyzés</u>: Cited By :1 Export Date: 17 November 2021 Correspondence Address: Valerieva, A.; Department of Allergology, Bulgaria; email: anna.valerieva@gmail.com</pre> </div></div>